Tumor growth limited to subcutaneous site vs tumor growth in pulmonary site exhibit differential effects on systemic immunities

Masuda,Junko; Takayama,Eiji; Strober,Warren; Satoh,Ayano; Morimoto,Yuji; Honjo,Yasuko; Ichinohe,Tatsuo; Tokuno,Shin-Ichi; Ishizuka,Toshiaki; Nakata,Takahiro; Mizutani,Akifumi; Umemura,Naoki; Kitani,Atsushi; Fuss,Ivan J.; Shigehiro,Tsukasa; Kawaki,Harumi; Mizuno-kamiya,Masako; Kondoh,Nobuo; Seno,Masaharu

doi:10.3892/or.2017.5646

Tumor growth limited to subcutaneous site vs tumor growth in pulmonary site exhibit differential effects on systemic immunities

Authors:
- Junko Masuda
- Eiji Takayama
- Warren Strober
- Ayano Satoh
- Yuji Morimoto
- Yasuko Honjo
- Tatsuo Ichinohe
- Shin-Ichi Tokuno
- Toshiaki Ishizuka
- Takahiro Nakata
- Akifumi Mizutani
- Naoki Umemura
- Atsushi Kitani
- Ivan J. Fuss
- Tsukasa Shigehiro
- Harumi Kawaki
- Masako Mizuno-kamiya
- Nobuo Kondoh
- Masaharu Seno
View Affiliations

Affiliations: Division of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama, Japan, Department of Oral Biochemistry, Asahi University School of Dentistry, Gifu, Japan, Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA, Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan, Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Verbal Analysis of Pathophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Pharmacology, National Defense Medical College, Saitama, Japan, Department of Molecular and Cellular Anatomy, Faculty of Health Promotional Science, Tokoha University, Hamamatsu, Japan
Published online on: May 17, 2017 https://doi.org/10.3892/or.2017.5646
Pages: 449-455

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To evaluate systemic immunity associated with tumor growth limited to a subcutaneous site versus growth proceeding at multiple tumor sites, we established syngeneic mouse subcutaneous and pulmonary tumor models by local subcutaneous and intravenous injection of colon carcinoma CT26 cells. We found that splenic myeloid-derived suppressor cell (MDSC) levels were significantly increased in the subcutaneous tumor model but not in the pulmonary tumor model. Furthermore, both CD4+ and CD8+ T cells as well as CD4+ Foxp3+ T cells were significantly decreased in the subcutaneous tumor model and were largely unchanged in the pulmonary tumor model. In addition, the subcutaneous model, but not the pulmonary model, displayed a Th1 polarization bias. This bias was characterized by decreased IL-4, IL-9, and IL-10 production, whereas the pulmonary model displayed increased production of IL-10. These results suggest that the mode of tumor development has differential effects on systemic immunity that may, in turn, influence approaches to treatment of cancer patients.

View Figures

View References

1	Liu Y, O'Leary CE, Wang LS, Bhatti TR, Dai N, Kapoor V, Liu P, Mei J, Guo L, Oliver PM, et al: CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. OncoImmunology. 5:e10611752015. View Article : Google Scholar : PubMed/NCBI
2	Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
3	Mougiakakos D, Choudhury A, Lladser A, Kiessling R and Johansson CC: Regulatory T cells in cancer. Adv Cancer Res. 107:57–117. 2010. View Article : Google Scholar : PubMed/NCBI
4	Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA and Strober W: Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res. 68:3467–3475. 2008. View Article : Google Scholar : PubMed/NCBI
5	Nagaraj S, Schrum AG, Cho H-I, Celis E and Gabrilovich DI: Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 184:3106–3116. 2010. View Article : Google Scholar : PubMed/NCBI
6	Alhamarneh O, Agada F, Madden L, Stafford N and Greenman J: Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck. 33:415–423. 2011.PubMed/NCBI
7	Shevach EM: Regulatory T cells in autoimmmunity. Annu Rev Immunol. 18:423–449. 2000. View Article : Google Scholar : PubMed/NCBI
8	Chen S, Akbar SMF, Abe M, Hiasa Y and Onji M: Immuno-suppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol. 166:134–142. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J and Ren X: Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 190:3783–3797. 2013. View Article : Google Scholar : PubMed/NCBI
10	Tsiganov EN, Verbina EM, Radaeva TV, Sosunov VV, Kosmiadi GA, Nikitina IY and Lyadova IV: Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice. J Immunol. 192:4718–4727. 2014. View Article : Google Scholar : PubMed/NCBI
11	Youn J-I, Nagaraj S, Collazo M and Gabrilovich DI: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 181:5791–5802. 2008. View Article : Google Scholar : PubMed/NCBI
12	Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Brencicova E, Escovar-Fadul X, Nguyen JM, Cadungog MG, et al: Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell. 27:27–40. 2015. View Article : Google Scholar : PubMed/NCBI
13	Wang JC, Kundra A, Andrei M, Baptiste S, Chen C, Wong C and Sindhu H: Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. Leuk Res. 43:39–43. 2016. View Article : Google Scholar : PubMed/NCBI
14	Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, et al: Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res. 76:2125–2136. 2016. View Article : Google Scholar : PubMed/NCBI
15	Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, et al: Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 116:5738–5747. 2010. View Article : Google Scholar : PubMed/NCBI
16	Pesu M, Watford WT, Wei L, Xu L, Fuss I, Strober W, Andersson J, Shevach EM, Quezado M, Bouladoux N, et al: T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature. 455:246–250. 2008. View Article : Google Scholar : PubMed/NCBI
17	Xu L, Kitani A, Stuelten C, McGrady G, Fuss I and Strober W: Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity. 33:313–325. 2010. View Article : Google Scholar : PubMed/NCBI
18	Alhamarneh O, Amarnath SMP, Stafford ND and Greenman J: Regulatory T cells: What role do they play in antitumor immunity in patients with head and neck cancer? Head Neck. 30:251–261. 2008. View Article : Google Scholar : PubMed/NCBI
19	Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S and Chen W: A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol. 9:632–640. 2008. View Article : Google Scholar : PubMed/NCBI
20	Gabitass RF, Annels NE, Stocken DD, Pandha HA and Middleton GW: Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 60:1419–1430. 2011. View Article : Google Scholar : PubMed/NCBI
21	Yamazaki T, Masuda J, Omori T, Usui R, Akiyama H and Maru Y: EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J Cell Sci. 122:243–255. 2009. View Article : Google Scholar : PubMed/NCBI
22	Takayama E, Seki S, Ohkawa T, Ami K, Habu Y, Yamaguchi T, Tadakuma T and Hiraide H: Mouse CD8+ CD122+ T cells with intermediate TCR increasing with age provide a source of early IFN-gamma production. J Immunol. 164:5652–5658. 2000. View Article : Google Scholar : PubMed/NCBI
23	Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
24	Terabe M, Matsui S, Park J-M, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, et al: Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J Exp Med. 198:1741–1752. 2003. View Article : Google Scholar : PubMed/NCBI
25	Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T and Wolchok JD: Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 13:412–424. 2015. View Article : Google Scholar : PubMed/NCBI
26	Yao Y, Vent-Schmidt J, McGeough MD, Wong M, Hoffman HM, Steiner TS and Levings MK: Tr1 cells, but not Foxp3+ regulatory T cells, suppress NLRP3 inflammasome activation via an IL-10-dependent mechanism. J Immunol. 195:488–497. 2015. View Article : Google Scholar : PubMed/NCBI
27	Redford PS, Murray PJ and O'Garra A: The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol. 4:261–270. 2011. View Article : Google Scholar : PubMed/NCBI
28	Saraiva M and O'Garra A: The regulation of IL-10 production by immune cells. Nat Rev Immunol. 10:170–181. 2010. View Article : Google Scholar : PubMed/NCBI
29	Beriou G, Bradshaw EM, Lozano E, Costantino CM, Hastings WD, Orban T, Elyaman W, Khoury SJ, Kuchroo VK, Baecher-Allan C, et al: TGF-beta induces IL-9 production from human Th17 cells. J Immunol. 185:46–54. 2010. View Article : Google Scholar : PubMed/NCBI
30	Zhao Y, Wu T, Shao S, Shi B and Zhao Y: Phenotype, development, and biological function of myeloid-derived suppressor cells. OncoImmunology. 5:e10049832015. View Article : Google Scholar : PubMed/NCBI
31	Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
32	Li J, Wang Z, Mao K and Guo X: Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer. Oncol Lett. 8:1682–1686. 2014.PubMed/NCBI
33	Hong C-C, Yao S, McCann SE, Dolnick RY, Wallace PK, Gong Z, Quan L, Lee KP, Evans SS, Repasky EA, et al: Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat. 139:477–488. 2013. View Article : Google Scholar : PubMed/NCBI
34	Liang J, Li Y, Liu X, Xu X and Zhao Y: Relationship between cytokine levels and clinical classification of gastric cancer. Asian Pac J Cancer Prev. 12:1803–1806. 2011.PubMed/NCBI
35	Seledtsov VI, Goncharov AG and Seledtsova GV: Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Hum Vaccin Immunother. 11:851–869. 2015. View Article : Google Scholar : PubMed/NCBI
36	Sato M, Goto S, Kaneko R, Ito M, Sato S and Takeuchi S: Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res. 18D:3951–3955. 1998.
37	Szaflarska A, Szczepanik A, Siedlar M, Czupryna A, Sierzega M, Popiela T and Zembala M: Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer. Anticancer Res. 29:5005–5012. 2009.PubMed/NCBI
38	Kozłowski L, Zakrzewska I, Tokajuk P and Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 48:82–84. 2003.PubMed/NCBI
39	Asadullah K, Sterry W and Volk HD: Interleukin-10 therapy - review of a new approach. Pharmacol Rev. 55:241–269. 2003. View Article : Google Scholar : PubMed/NCBI
40	Habu Y, Seki S, Takayama E, Ohkawa T, Koike Y, Ami K, Majima T and Hiraide H: The mechanism of a defective IFN-γ response to bacterial toxins in an atopic dermatitis model, NC/Nga mice, and the therapeutic effect of IFN-γ, IL-12, or IL-18 on dermatitis. J Immunol. 166:5439–5447. 2001. View Article : Google Scholar : PubMed/NCBI
41	Noelle RJ and Nowak EC: Cellular sources and immune functions of interleukin-9. Nat Rev Immunol. 10:683–687. 2010. View Article : Google Scholar : PubMed/NCBI
42	Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J, et al: Th9 cells promote antitumor immune responses in vivo. J Clin Invest. 122:4160–4171. 2012. View Article : Google Scholar : PubMed/NCBI
43	Huang Y, Cao Y, Zhang S and Gao F: Association between low expression levels of interleukin-9 and colon cancer progression. Exp Ther Med. 10:942–946. 2015.PubMed/NCBI